Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.

Abstract

The influence of renal insufficiency on melphalan-induced myelosuppression was examined during the initial 10 weeks of treatment in 295 patients with multiple myeloma. Patients were randomized to receive either oral melphalan (0.15 mg/kg/day for 7 days, followed by 0.05 mg/kg/day after recovery from the wbc count nadir) or iv melphalan (16 mg/m2 every 2… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.